Early postseroconversion CD4 cell counts independently predict CD4 cell count recovery in HIV-1-postive subjects receiving antiretroviral therapy

Journal of Acquired Immune Deficiency Syndromes

Volumn 57, Issue 5, 2011, Pages 387-395

  Kulkarni, Hemant ^a,b   Okulicz, Jason F ^c,d   Grandits, Greg ^c,e   Crum Cianflone, Nancy F ^c,f   Landrum, Michael L ^c,d   Hale, Braden ^c,f   Wortmann, Glenn ^c,g   Tramont, Edmund ^c,h   Polis, Michael ^c,h   Dolan, Matthew ⁱ   Lifson, Alan R ^e   Agan, Brian K ^c   Ahuja, Sunil K ^a,b,j   Marconi, Vincent C ^c,k  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b Mays Cancer Center at UT Health San Antonio   (United States)

^c UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^d SAN ANTONIO MILITARY MEDICAL CENTER   (United States)

^e UNIVERSITY OF MINNESOTA   (United States)

^f NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^g WALTER REED ARMY MEDICAL CENTER   (United States)

^h NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

ⁱ HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE   (United States)

^j UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^k EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

CD4 count; highly active antiretroviral therapy; outcomes; predictors; treatment response

Indexed keywords

ANTIRETROVIRUS AGENT;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; DISEASE COURSE; FEMALE; HEALTH CARE ACCESS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; HIV INFECTIONS; HIV SEROPOSITIVITY; HIV-1; HUMANS; PREDICTIVE VALUE OF TESTS; VIRAL LOAD;

EID: 80051550219     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182219113     Document Type: Article

References (45)

1. Tan R, Westfall AO, Willig JH, et al. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:553-558. (Pubitemid 351442024)
2. Grabar S, Le Moing V, Goujard C, et al. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133: 401-410.
3. van Griensven J, Zachariah R, Rasschaert F, et al. Discordant immunologic and virologic responses to antiretroviral therapy and associated mortality in a large treatment program in Rwanda. J Acquir Immune Defic Syndr. 2009;50:556-558.
4. Moore DM, Hogg RS, Chan K, et al. Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response. AIDS. 2006;20:371-377.
5. Valdez H, Connick E, Smith KY, et al. Limited immune restoration after 3 years' suppression of HIV-1 replication in patients with moderately advanced disease. AIDS. 2002;16:1859-1866.
6. Moore DM, Hogg RS, Yip B, et al. Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy. J Acquir Immune Defic Syndr. 2005;40:288-293. (Pubitemid 41533068)
7. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. (Pubitemid 44837777)
8. Achhra AC, Amin J, Law MG, et al. Immunodeficiency and the risk of serious clinical endpoints in a well studied cohort of treated HIV-infected patients. AIDS. 2010;24:1877-1886.
9. Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS. 2007;21:169-178. (Pubitemid 46036924)
10. Mussini C, Bedini A, Borghi V, et al. CD4 cell-monitored treatment interruption in patients with a CD4 cell count . 500 x 106 cells/l. AIDS. 2005;19:287-294. (Pubitemid 40396560)
11. Miller V, Mocroft A, Reiss P, et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med. 1999;130:570-577. (Pubitemid 29169384)
12. Sterling TR, Chaisson RE, Moore RD. HIV-1 RNA, CD4 T-lymphocytes, and clinical response to highly active antiretroviral therapy. AIDS. 2001; 15:2251-2257. (Pubitemid 34059832)
13. Egger M, May M, Chene G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet. 2002;360:119-129. (Pubitemid 34786200)
14. Anastos K, Barron Y, Miotti P, et al. Risk of progression to AIDS and death in women infected with HIV-1 initiating highly active antiretroviral treatment at different stages of disease. Arch Intern Med. 2002;162: 1973-1980.
15. Kaplan JE, Hanson DL, Cohn DL, et al. When to begin highly active antiretroviral therapy? Evidence supporting initiation of therapy at CD4+ lymphocyte counts ,350 cells/microL. Clin Infect Dis. 2003;37:951-958. (Pubitemid 37267212)
16. Tarwater PM, Gallant JE, Mellors JW, et al. Prognostic value of plasma HIV RNA among highly active antiretroviral therapy users. AIDS. 2004; 18:2419-2423. (Pubitemid 40065909)
17. Kitahata MM, Gange SJ, Abraham AG, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360:1815-1826.
18. Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000;14:141-149. (Pubitemid 30116439)
19. Kaufmann GR, Bloch M, Zaunders JJ, et al. Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. AIDS. 2000;14:959-969. (Pubitemid 30336056)
20. Florence E, Lundgren J, Dreezen C, et al. Factors associated with a reduced CD4 lymphocyte count response to HAART despite full viral suppression in the EuroSIDA study. HIV Med. 2003;4:255-262. (Pubitemid 36949882)
21. Hunt PW, Deeks SG, Rodriguez B, et al. Continued CD4 cell count increases in HIV-infected adults experiencing 4 years of viral suppression on antiretroviral therapy. AIDS. 2003;17:1907-1915. (Pubitemid 37070276)
22. Robbins GK, Spritzler JG, Chan ES, et al. Incomplete reconstitution of T cell subsets on combination antiretroviral therapy in the AIDS Clinical Trials Group protocol 384. Clin Infect Dis. 2009;48: 350-361.
23. Kaufmann GR, Bloch M, Finlayson R, et al. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. Aids. 2002;16:359-367. (Pubitemid 34165367)
24. Kaufmann GR, Furrer H, Ledergerber B, et al. Characteristics, determinants, and clinical relevance of CD4 T cell recovery to ,500 cells/microL in HIV type 1-infected individuals receiving potent antiretroviral therapy. Clin Infect Dis. 2005;41:361-372. (Pubitemid 41022115)
25. Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-446. (Pubitemid 46147630)
26. Wu H, Connick E, Kuritzkes DR, et al. Multiple CD4+ cell kinetic patterns and their relationships with baseline factors and virological responses in HIV type 1 patients receiving highly active antiretroviral therapy. AIDS Res Hum Retroviruses. 2001;17:1231-1240. (Pubitemid 32911626)
27. Viard JP, Mocroft A, Chiesi A, et al. Influence of age on CD4 cell recovery in human immunodeficiency virus-infected patients receiving highly active antiretroviral therapy: evidence from the EuroSIDA study. J Infect Dis. 2001;183:1290-1294. (Pubitemid 32281572)
28. Lederman MM, McKinnis R, Kelleher D, et al. Cellular restoration in HIV infected persons treated with abacavir and a protease inhibitor: age inversely predicts naive CD4 cell count increase. AIDS. 2000;14: 2635-2642. (Pubitemid 32118716)
29. Ferraris L, Bellistri GM, Pegorer V, et al. Untangling the immunological implications of nadir on CD4+ cell recovery during suppressive highly active antiretroviral therapy. Clin Infect Dis. 2008;46:149-150. (Pubitemid 351263579)
30. Weintrob AC, Grandits GA, Agan BK, et al. Virologic response differences between African Americans and European Americans initiating highly active antiretroviral therapy with equal access to care. J Acquir Immune Defic Syndr. 2009;52:574-580.
31. Marconi VC, Grandits GA, Weintrob AC, et al. Outcomes of highly active antiretroviral therapy in the context of universal access to healthcare: the U.S. Military HIV Natural History Study. AIDS Res Ther. 2010;7:14.
32. Marconi VC, Grandits G, Okulicz JF, et al. 2011 Cumulative Viral Load and Virologic Decay Patterns after Antiretroviral Therapy in HIV-Infected Subjects Influence CD4 Recovery and AIDS. PLoS ONE. 2011;6:17956.
33. Ahuja SK, Kulkarni H, Catano G, et al. CCL3L1-CCR5 genotype influences durability of immune recovery during antiretroviral therapy of HIV-1-infected individuals. Nat Med. 2008;14:413-420. (Pubitemid 351499392)
34. From the Centers for Disease Control and Prevention. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. JAMA. 1993;269: 729-730.
35. Gazzola L, Tincati C, Bellistri GM, et al. The absence of CD4+ T cell count recovery despite receipt of virologically suppressive highly active antiretroviral therapy: clinical risk, immunological gaps, and therapeutic options. Clin Infect Dis. 2009;48:328-337.
36. Torti C, Cologni G, Uccelli MC, et al. Immune correlates of virological response in HIV-positive patients after highly active antiretroviral therapy (HAART). Viral Immunol. 2004;17:279-286. (Pubitemid 38880427)
37. Mellors JW, Munoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-954. (Pubitemid 27255797)
38. Rodriguez B, Sethi AK, Cheruvu VK, et al. Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection. JAMA. 2006;296:1498-1506. (Pubitemid 44465514)
39. Battegay M, Nuesch R, Hirschel B, et al. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006;6:280-287.
40. Schacker TW, Bosch RJ, Bennett K, et al. Measurement of naive CD4 cells reliably predicts potential for immune reconstitution in HIV. J Acquir Immune Defic Syndr. 2010;54:59-62.
41. Brenchley JM, SilvestriG, Douek DC. Nonprogressive and progressive primate immunodeficiency lentivirus infections. Immunity. 2010;32:737-742.
42. Margolick JB, Gange SJ, Detels R, et al. Impact of inversion of the CD4/CD8 ratio on the natural history of HIV-1 infection. J Acquir Immune Defic Syndr. 2006;42:620-626. (Pubitemid 44162434)
43. Caruso A, Licenziati S, Canaris AD, et al. Contribution of CD4+, CD8+CD28+, and CD8+CD28-T cells to CD3+ lymphocyte homeostasis during the natural course of HIV-1 infection. J Clin Invest. 1998;101: 137-144.
44. Amadori A, Zamarchi R, Chieco-Bianchi L. CD4: CD8 ratio and HIV infection: the "tap-and-drain" hypothesis. Immunol Today. 1996;17: 414-417. (Pubitemid 26278365)
45. Lifson AR, Krantz EM, Eberly LE, et al. Long-term CD4+ lymphocyte response following HAART initiation in a U.S. Military prospective cohort. AIDS Res Ther. 2011;8:2.